

## The treatment of infantile hemangiomas, a Bordeaux discovery accompanied by SATT Aquitaine, now arrives in China

In November of 2018, **PIERRE FABRE DERMATOLOGIE** (Hereinafter “**PFD**”, a subsidiary of **PIERRE FABRE GROUP**) and **WUHAN CONFORM PHARMACEUTICAL Co. Ltd** (Hereinafter “**CONFORM**”, a subsidiary of **HUMANWELL GROUP**) signed a patent License Agreement. PFD has granted to CONFORM an exclusive license to produce and sell propranolol oral solution for the treatment of infantile hemangiomas in China. The granted patent License Agreement of CONFORM originated from the university in Bordeaux (Hereinafter “Bordeaux university”) and University Hospital Center of Bordeaux (CHU of Bordeaux) who were first in the world to discover that propranolol could treat infantile hemangiomas. Subsequently, Bordeaux university and CHU of Bordeaux have granted PFD an exclusive license to exploit worldwide and the right to sub-license a treatment of infantile hemangiomas based on their discovery and their patents.

Propranolol oral solution Hemangioli by PFD is the first and only drug approved by the American FDA and the EMA for the treatment of infantile hemangiomas. CONFORM is the subsidiary of HUMANWELL GROUP, HUMANWELL GROUP belongs to the Top 30 pharmaceutical companies in China. CONFORM is the first company who submit the clinical application of propranolol oral solution in infantile hemangioma to CFDA. CONFORM’S application of the product entered the list of children’s urgent need drugs in China, and received the qualification of accelerated review of the product. Recently, CONFORM has submitted the application to CFDA for market authorization. CONFORM’S propranolol oral solution product should go to the market in China in 2019 to satisfy treatment need of Chinese babies suffering from infantile hemangiomas.

: Établissement principal  
: Bâtiment A31, 3ème étage  
: 351 cours de la Libération  
: 33405 TALENCE Cedex  
: Tél. : 05 33 51 43 00

: Établissement secondaire  
: Avenue de l’Université - BP 81121  
: 64011 PAU Cedex  
: Tél. : 05 40 17 52 92

: Siège social  
: 166, cours de l’Argonne  
: 33000 BORDEAUX

[www.ast-innovations.com](http://www.ast-innovations.com)

SATT Aquitaine SAS au capital de 1 000 000 d’euros - RCS Bordeaux 753 027 663 - TVA FR46 753 027 663

